N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=100 Supportive and Supportive-Expressive Treatment for Depression
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HRSD) — 12.32; 12.06; 20.20; 20.08 units on a scale — p=.016
N/A N=94 Stress and the Sympathetic Nervous System in Adults With Depression
Major Depressive Disorder
Primary: Percent of Days Participants Report Stressors — 36; 40 percent of days
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
N/A N=64 Virtual Reality Compared to Screen Based Engagement on Mood
Virtual Reality
Primary: Change in Positive Affect and Negative Affect From Baseline to After a 2 Minute Mood Induction — 3.7; 4.63; 1.97; 1.56 units on a scale
Phase 4 N=30 Duloxetine Treatment in Elderly With Dysthymia
Depression · Dysthymic Disorder
Primary: Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks. — 8 units on a scale — p=<0.001
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
N/A N=1,385 Sleep to Prevent Evolving Affecting Disorders
Insomnia, Primary · Depression
Primary: Severity of Depression as Measured by the Quick Inventory of Depressive Symptomatology (QIDS) Pre-Treatment — 10.8; 10.8 score on a scale
Phase 1 N=64 Lipopolysaccharide (LPS) Challenge in Depression
Major Depressive Disorder
Primary: Change in Snaith-Hamilton Pleasure Scale (SHAPS) — 38.4; 33.2; 27.2; 26.2 units on a scale
Phase 4 N=85 Advancing Personalized Antidepressant Treatment Using PET/MRI
Depression
Primary: Change From Baseline in Hamilton Depression Rating Scale at 8 Weeks — 11.81; 9.41 score on a scale
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
Phase 4 N=16 Identifying and Treating Depression in Hemodialysis Patients
Depression · Hemodialysis-Induced Symptom
Primary: To Determine the Impact of Directly Observed Weekly Fluoxetine Treatment on Remission of Depression Among Hemodialysis Patients. — 6.6 units on a scale
N/A N=36 Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition
Postpartum Depression
Primary: Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z Statistic — 2.3; 2.0; 2.1; 1.7 z score — p=.27
N/A N=26 Transcranial Direct Current Stimulation Therapy for Major Depression
Major Depressive Disorder
Primary: Clinical Response — 22 Participants
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
Phase 4 N=53 Effects of Treatment on Decision-making in Major Depression
Major Depressive Disorder · Healthy Controls
Primary: Money Earned — 23.2; 25.0; 20.5; 21.9 US Dollars
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
N/A N=851 Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Percentage of Participants With Remission Based on Hamilton Depression Scale (HAM-D) — 54.4 Percentage of participants
N/A N=21 A Pilot Study of the Immediate Effects of DLPFC tDCS on Attention Bias in Depression
Depression
Primary: Beck Depression Inventory (BDI-II) Score — 21.29 score on a scale
Phase 2 N=12 Pramipexole to Target "Anhedonic Depression"
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
N/A N=141 Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Pulmonary Disease, Chronic Obstructive · Major Depression
Primary: Composite Antidepressant Score Scale (CAD) — 29; 25; 9; 20 Participants
N/A N=12,909 Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
Major Depressive Disorder · Major Depressive Episode
Primary: Major Depressive Disorder (MDD) Composite: Positive Patient Health Questionnaire-9 (PHQ-9; Universal Arm) or MDD Concern Prompting Student Assistance Program (SAP)…
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
N/A N=500 Preventing Depressive Relapse in Pregnant Women With Recurrent Depression
Depression · Pregnancy Related · Antenatal Depression
Primary: Number of Participants Experiencing Relapse of Depression — 81; 111 Participants
Phase 2 N=296 Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
Depression
Primary: Hamilton Rating Scale for Depression — 11.06; 12.52 units on a scale
N/A N=80 Coping With Depression in Parkinson's Disease
Parkinson's Disease · Depression
Primary: Hamilton Depression Rating Scale: Baseline — 20.93; 19.38 units on a scale
Phase 4 N=40 Depression, Epinephrine, and Platelet Function
Major Depressive Disorder
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8 — 5; 9; 2; 4 participants — p=.918
Phase 4 N=40 Predictors of Antidepressant Response
Depression
Primary: Changes in Mu-opioid Binding Potential During PET — 0.12 Binding potential ratio — p=<0.001
N/A N=2,452 Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19
Depression
Primary: Change in Adolescent Depressive Symptom Severity — 14.31; 14.15; 14.22; 12.57 Score on a scale